5 papers about lung cancer suggested by Stephen Liu

Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:

1. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Authors: Aaron Mansfield et al.

2. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study

Authors: Jyoti Malhotra, Alberto Chiappori, Naomi Fujioka, Nasser Hanna, Lawrence Feldman, Malini Patel, Dirk Moore, Chunxia Chen, Salma Jabbour

3. Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors

Authors: Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn

4. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer

Authors: Bolun Zhou et al.

5. Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial

Authors: Peter Grimison et al.

Follow Stephen Liu on X for more such content.

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.